ClinicalTrials.gg
RecruitingNCT06986070SORT-COPDUpdated Aug 11, 2026

Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

A Phase 1 interventional study of Stem cells in Chronic Obstructive Lung Disease, sponsored by SMSbiotech. Recruiting at 1 site in Australia. Open to participants aged 39 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by SMSbiotech · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
39 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia — 15 open to participants now, 19 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Australia.

Planned enrollment
126th of 132
18 · median 441
Started
2025
with 8 others
Phase 1
14 of 140
4 open now
Primary completion
2026-12
later than 5 of 18 live
Registered
130th of 140
by date

Among the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, this one is the 126th largest by planned enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2025, is one of 14 in phase 1, reaches primary completion later than 5 of the 18 other live ones, and was the 130th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 39 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, or all of them as a file.
02

Study summary

This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells).

The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.

Read the detailed description

The suspension of stem cells will be put in a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. This means that the participants will breathe in the mist containing the SMS cells, produced by the nebulizer machine. This is a Phase I First-in-Human study, which indicates that this treatment is being studied for the first time in humans.

18 participants are expected to be enrolled into this study. Participants will be divided into three groups of six volunteers, with the first group receiving the lowest dose of the study treatment, the second group receiving a higher dose, and the third group receiving the highest dose. Between each of the three groups, there will be a pause to permit detection of any short-term adverse effects of the treatment at a specific dose.

Participants will be treated with the study drug, SORT COPD (Small Mobile Stem Cells), delivered via a medical nebuliser on the 1st, 4th, and the 8th days of the study in-clinic. The nebuliser treatment involves inhaling mist from a mouthpiece attached to a standard medical nebuliser machine and takes about 10 to 15 minutes to complete.

The volume to be nebulised is 3 millilitres (less than one teaspoon). Participants in the cohort 1 (low dose) will receive 1.2 billion cells/ml. Participants in the cohort 2 (medium dose) will receive 2.4 billion cells/ml. Participants in the cohort 3 (high dose) will receive 4.8 billion cells/ml.

The study treatment (SMS) cells will be given in three different concentrations with the lowest dose given to the 1st group of 6 participants, with the dose doubled for each group. The members of each group will receive the same dose at each treatment visit.

Participants will actively be in the study for up to 5 or 6 weeks, including the initial screening and testing period before the treatment is applied, during treatment, and about 4 weeks after the first treatment. Also, about 3 to 6 months after the study, participants will be contacted via telephone to answer some questions about their state of health, which will be the end of the study.

Individual participant duration will be up to a maximum of 15 months.

03

Conditions studied

  • Chronic Obstructive Lung Disease
04

Who can participate

Ages eligible
39 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 39 to 69 years (inclusive).
  2. Female participants:

    A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    Is a woman of nonchildbearing potential (WONCBP) OR Is a woman of (WOCBP) and using an acceptable method from screening until 30 days after the last dose of study intervention.

    A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) at Screening and on Day 1, prior to administration of study intervention.

    If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

    The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

  3. Male participants:

    Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 30 days after the last dose of study intervention:

    Refrain from donating fresh unwashed semen. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception/barrier (male condom).

  4. Has a diagnosis of mild or moderate -C (cigarette smoking COPD) or COPD-P (biomass and pollution exposure COPD) according to the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Criteria.

    Lung impairment will be determined with post-bronchodilator spirometry.

  5. Has previously received treatment for COPD-C or COPD-P.
  6. Has stable COPD disease state, defined as no exacerbations in the 12 weeks prior to screening, no hospitalizations in the 12 weeks prior to screening, and no changes in COPD medication in the 28 days prior to screening.
  7. Agrees to comply with study specific procedures and visits, including non-smoking during the treatment and follow-up periods of the study.
  8. Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Previous or current diagnosis of -G, COPD-D, COPD-I, COPD-A or COPD-U; asthma, congestive heart failure, bronchiectasis, tuberculosis, obliterative bronchiolitis or diffuse panbronchiolitis.
  2. Previous or current history of respiratory failure other than due to COPD (e.g. restrictive lung disease, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, CMV pneumonitis, cystic fibrosis, asbestosis, silicosis or farmer's lung disease), or detection of any of these conditions through screening CT scanning.
  3. History of COVID associated pneumonia with hypoxemic respiratory failure in the 12 weeks prior to screening.
  4. Current use, or use within 21 days of screening, of systemic . Participants on inhaled corticosteroids or combined inhaled therapies can be included, however must schedule inhaled therapies 12 hours prior to dosing IP and 12-hours post dosing IP.
  5. Any history of chronic liver disease, or abnormal liver function at screening, defined as:

    (ALT) and/or aspartate aminotransferase (AST) more than 2.5 times the (ULN) Total more than two times the ULN Participants with documented Gilbert's syndrome are permitted to enter the study.

  6. History of chronic renal insufficiency, defined as and \< 90 mL/min/1.73 m2. Participants without a history of chronic renal insufficiency, who at screening have an eGFR detected between 60-89 mL/min/1.73 m2, should have their eGFR repeated as per standard clinical procedure.
  7. Uncontrolled hypertension, or current hypertension controlled on more than two medications.
  8. History, within the last two years, of coronary artery disease, coronary artery bypass graft surgery, percutaneous transluminal coronary angioplasty, severe peripheral arterial disease, cerebrovascular disease (including history of or cerebrovascular accident), or any such history that, in the opinion of the investigator, will impact participation in the study.
  9. Type 1 or Type 2 diabetes mellitus with glycosylated ( > 7.5%) at screening.
  10. No active in the last three years, including any potential neoplasm detected via high-resolution CT scan (nodule > 5 mm) detected as part of the screening process.

    People with a history of basal cell or squamous cell carcinoma of the skin are eligible.

  11. History of or other conditions, or , or use of immunosuppressive medications within 14 days prior to screening, and for 3 weeks after the last dose of study intervention is administered.
  12. Active infection requiring systemic antibiotic treatment within 12 weeks prior to screening.
  13. (BMI) > 60 kg/m2.
  14. Active smoking of tobacco, cannabis or vaping in the 28 days prior to screening as indicated by results of cotinine urine testing, performed at screening. Use of nicotine containing products such as nicotine patches, oral nicotine products or nicotine chewing gum is permitted, noting that cotinine results will be positive. Positive results will be documented by the investigator as "attributed to permitted nicotine products".
  15. History of alcohol or other substance abuse, with sobriety less than one year, or that in the opinion of the investigator, will impact participation in the study.
  16. Pregnant or breastfeeding.
  17. Any severe medication allergy, including an allergy to bovine products.
  18. Any other medical condition, psychiatric condition or illness, that according to the Principal Investigator might render the subject unlikely to tolerate the inhalation of SORT-COPD (SMS cells), or to complete the study.
  19. Current participation in any other clinical trial or participation in the last six weeks or subject received an experimental therapy (drug or biologic) for any indication within 12 months prior to enrolment.
  20. Unable or unwilling to comply with study specific schedules or procedures.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Participants in the cohort 1 (low dose) will receive 1.2 billion cells/ml.

    Dose escalating Cohort 1.

    Biological: Stem cells

  • Experimental
    Participants in the cohort 2 (medium dose) will receive 2.4 billion cells/ml.

    Dose escalating Cohort 2.

    Biological: Stem cells

  • Experimental
    Participants in the cohort 3 (high dose) will receive 4.8 billion cells/m

    Dose Escalating Cohort 3.

    Biological: Stem cells

Interventions

  • BiologicalStem cells

    The suspension of stem cells will be put in a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. This means that the participants will breathe in the mist containing the SMS cells, produced by the nebulizer machine. This is a Phase I First-in-Human study, which indicates that this treatment is being studied for the first time in humans.

    Also known as: Small Molecule Stem (SMS) Cells

06

What researchers measure

Primary outcomes

  1. Adverse events.

    Treatment emergent adverse events and serious adverse events.

    Time frame: Day 1, 2, 3, 4, 5, 8, 9, 21, 28, Month 3 and Month 6.

  2. Dose limiting toxicity.

    Any treatment emergent adverse event that ii treatment related and classified as severe or the event is classified as a serious adverse event.

    Time frame: Day 1, 2, 3, 4, 5, 8, 9, 21, 28, Month 3 and Month 6.

  3. Safety laboratory testing

    All laboratory parameters will be summarized using descriptive statistics for each cohort and overall, for all time points assessed, including change from baseline for all post-dose assessments. Selected laboratory test results will be graded in accordance with the NCI CTCAE criteria.

    Time frame: Screening, Day 2, 3, 5, 9, 21 and 28.

Secondary outcomes

  1. Spirometry

    To be performed according to the American Thoracic Society/European Respiratory Society Standards. Forced Expiratory Volume in 1 second (FEV1) measured in liters (L).

    Time frame: Screening, Day 1, 2, 3, 4, 5, 8, 9, 21 and 28.

  2. Spirometry

    To be performed according to the American Thoracic Society/European Respiratory Society Standards. Forced Vital Capacity (FVC) measured in liters (L).

    Time frame: Screening, Day 1, 2, 3, 4, 5, 8, 9, 21 and 28.

  3. Oscillometry

    Resistance measured in cm H2O s/L .

    Time frame: Screening, Day 1 and 28.

  4. Oscillometry

    Resistance change measured in cm H2O s/L..

    Time frame: Screening, Day 1 and 28.

  5. Oscillometry

    Reactance of respiratory system measured in cm H2O s/L.

    Time frame: Screening, Day 1 and 28.

  6. Plethysmograhy

    Functional Residual Capacity (FRC) measured in liters (L).

    Time frame: Screening and Day 28.

  7. Plethysmograhy

    Total Lung Capacity (TLC) measured in liters (L).

    Time frame: Screening and Day 28.

  8. Plethysmograhy

    Ratio of Residual Volume measured as a percentage (%).

    Time frame: Screening and Day 28.

  9. Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)

    DLCO measured in milliliters per min per millimeter of Mercury (mL/min/mmHg).

    Time frame: Screening and Day 28.

  10. Pulse oximetry

    Measuring oxygen saturation in the participants blood (SpO2)

    Time frame: Screening, Day 1, 2, 3, 4, 5, 8, 9, 21 and 28.

  11. 6-minute walk-test

    Assessment of exercise tolerance , distance walked in 6-minutes measured in meters (m).

    Time frame: Screening, Day 1, 5, 9, 21 and 28.

  12. Exhaled Nitirc Oxide Test

    The fractional exhaled nitric oxide (FENO) test measures the amount of nitric oxide that is exhaled from a breath. It is a marker of lung inflammation, and is useful for differentiating asthma from COPD and other conditions presenting with similar symptoms \[26\]. FENO values of \< 25 parts per billion (ppb) are considered normal, 25-50 ppb as intermediate and \> 50 ppb as high.

    Time frame: Screening, Day 1, 2, 3, 4, 5, 8, 9, 21 and 28.

  13. St George Respiratory Questionnaire for COPD

    Measurement of quality of life validated for participants with COPD. Each subscale and the total score range from 0 (no impact) to 100 (worst possible impact).

    Time frame: Screening, Day 1, Day 28, Month 3 and Month 6.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — De-identified data will be published in a peer review scientific journal or presented at a scientific conference. There is no plan at this stage to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 18 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
May 22, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06986070
Lead sponsor
SMSbiotech
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jun 13, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion